SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (258)1/26/1999 12:39:00 PM
From: Abuckatatime   of 613
 
TD,

Diatide (DITI). Radiolabelled peptides for medical imaging. AcuTect approved last fall for detection of deep venous thrombi. NeoTect under fast-track review for diagnosing lung malignancies. Both of these products developed and sold in JV with Nycomed.

I've bought and sold a couple of times. Currently watching...for quarterly results that will give some indication of sales of Acutect. I'm concerned that while DITI's products may have significant advantages over current diagnostic tools, that it may take a while for DITI and Nycomed to gain significant market acceptance of their products.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News